Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis

We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizoti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Takashi, Kanda, Shintaro, Fukushima, Toshirou, Noguchi, Takuro, Sekiguchi, Nodoka, Koizumi, Tomonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365006/
https://www.ncbi.nlm.nih.gov/pubmed/34184417
http://dx.doi.org/10.1111/1759-7714.14056
Descripción
Sumario:We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizotinib and alectinib resistance mutation. Subsequent therapy with the third‐generation ALK inhibitor lorlatinib, but not ceritinib, showed antitumor activity for 1 year. The uterus is an uncommon site for metastasis from lung cancer, and our case indicated that serial gene analysis could provide new information about ALK inhibitor resistance.

Ejemplares similares